Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) announced on 28 July 2026 that its Board of Directors has approved the appointment of Shanti Ekambaram as an Additional Independent Director for a term of three consecutive years effective 30 July 2026, subject to shareholder approval. Ekambaram, holding Designation Identity Number 00004889, brings 39 years of financial services experience, including 35 years at Kotak Mahindra Bank where she served as Deputy Managing Director and Whole-time Director from 2022 to 2025.
Key Highlights
- Shanti Ekambaram appointed as Additional Independent Director of Torrent Pharmaceuticals for three consecutive years commencing 30 July 2026, pending shareholder approval.
- Ekambaram, aged 63, is a Chartered Accountant and Cost Accountant with 39 years of experience in financial services and banking sector leadership.
- She previously served as Deputy Managing Director and Whole-time Director at Kotak Mahindra Bank, overseeing Digital Banking, Treasury, Human Resources, and Internal Audit functions.
- Ekambaram currently serves on the boards of Kotak Mahindra Capital Company, Kotak Securities, Havells India Limited, and Indian Institute of Management Bangalore.
- She is not related to any other Director of Torrent Pharmaceuticals and is not debarred from holding office under any SEBI or regulatory order.
- The appointment was recommended by the Nomination and Remuneration Committee and follows SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
About the Company
Torrent Pharmaceuticals Limited is a BSE and NSE-listed Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. Listed on the National Stock Exchange under ticker TORNTPHARM and on the Bombay Stock Exchange with scrip code 500420, the company manufactures and markets a diverse portfolio of pharmaceutical products across therapeutic areas including cardiovascular, gastroenterology, central nervous system, dermatology, and respiratory segments. Torrent operates manufacturing facilities across India and distributes its products through retail pharmacy channels and institutional customers. The company is part of the Torrent Group, a diversified business conglomerate with interests in pharmaceuticals, agrochemicals, and water treatment solutions.
Announcement in Detail
Torrent Pharmaceuticals disclosed on 28 July 2026 that its Board of Directors, acting on the recommendation of the Nomination and Remuneration Committee, has approved the appointment of Shanti Ekambaram (DIN: 00004889) as an Additional Independent Director. The appointment is effective from 30 July 2026 and is for a period of three consecutive years, contingent upon shareholder approval. The company confirmed that Ekambaram is not related to any existing Director and is not subject to any debarment order issued by SEBI or any other regulatory authority, confirming her eligibility to hold the office.
Ekambaram brings substantial institutional experience to the Board. She spent 35 years at Kotak Mahindra Bank, where she held progressively senior roles and, most recently, served as Deputy Managing Director and Whole-time Director from 2022 to 2025. During her tenure, she provided strategic oversight of Digital Banking, Treasury, Human Resources, Internal Audit, Vigilance, Corporate Social Responsibility and Environment, Social and Governance functions, and Capital Market subsidiaries. Prior to this role, she was Chief Executive Officer of Kotak Mahindra Capital Company from 1997 to 2003, the investment banking joint venture between Kotak and Goldman Sachs, where she led initiatives including the Hughes Software IPO in 1999, the country's first book-building transaction.
The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, with full details provided in compliance with the SEBI Master Circular dated 30 January 2026. Ekambaram is a qualified Chartered Accountant and Cost Accountant. She currently holds directorships at Kotak Mahindra Capital Company, Kotak Securities, Havells India Limited, and the Indian Institute of Management Bangalore, where she contributes to governance and strategic oversight.
Impact on Investors
The appointment strengthens the Board's independence and governance profile. Investors will note that an Additional Independent Director expands the Board's supervisory capacity and brings external perspectives to decision-making. Ekambaram's extensive background in banking, capital markets, digital transformation, and institutional governance may enhance the Board's ability to assess strategic, operational, and regulatory matters relevant to the pharmaceutical sector. Her track record in leading large-scale financial and business transformation initiatives at a major banking institution adds depth to the Board's oversight of management performance and corporate governance standards.
The filing shows that the appointment is subject to shareholder approval, a procedural requirement under the Companies Act, 2013 and the Listing Regulations. Shareholders will be required to ratify this appointment, likely at an upcoming annual general meeting or extraordinary general meeting. No financial implications or material contract awards are disclosed in relation to this appointment. Investors should monitor the company's notice of shareholder meeting and voting outcome to confirm formal approval of this Board change. The appointment does not result in any change to the company's capital structure, dividend policy, or outstanding debt.
Sector / Market Context
Independent Board appointments have become a focus area for Indian regulators and institutional investors as part of broader corporate governance reforms. The SEBI Listing Obligations and Disclosure Requirements Regulations, 2015 mandate that listed companies maintain a minimum proportion of independent directors and establish Board committees including Nomination and Remuneration, Audit, and Risk Management committees. Independent directors bring external expertise, reduce conflicts of interest, and strengthen oversight of management and related-party transactions. The pharmaceutical sector in particular has seen increasing emphasis on Board diversity, including gender representation and cross-functional expertise, as institutional investors and asset owners prioritize governance metrics when evaluating investment decisions.